Value of Clinical Pulmonary Infection Score in guiding treatment of tigecycline combined with cefoperazone sodium and sulbactam sodium for severe pneumonia patients
-
摘要: 目的 探讨临床肺部感染评分(CPIS)指导替加环素联合头孢哌酮钠舒巴坦钠治疗重症肺炎的价值。 方法 选取重症肺炎患者60例,随机分为2组,每组30例。对照组根据经验应用抗菌药治疗,观察组在CPIS指导下应用抗菌药治疗,用药方案均为替加环素联合头孢哌酮钠舒巴坦钠。比较2组症状消失率、抗菌药应用时间、炎症指标［C反应蛋白(CRP)、降钙素原(PCT)、白细胞计数(WBC)］水平及不良反应。 结果 治疗2周时, 2组患者发热症状均消失, 2组肺啰音、咳痰的消失率比较,差异无统计学意义(P>0.05)。观察组抗菌药应用时间为(7.38±2.66)d, 短于对照组的(9.82±2.89)d, 差异有统计学意义(t=3.403, P=0.001)。2组患者治疗后的CRP、PCT、WBC水平均较治疗前降低,差异有统计学意义(P<0.05)。观察组不良反应发生率低于对照组,差异有统计学意义(P<0.05)。 结论 在CPIS的指导下采用替加环素联合头孢哌酮钠舒巴坦钠治疗重症肺炎安全、有效,可缩短用药时间,缓解患者症状。Abstract: Objective To investigate the value of Clinical Pulmonary Infection Score(CPIS)in guiding the treatment of tigecycline combined with cefoperazone sodium and sulbactam sodium for severe pneumonia patients. Methods Totally 60 patients with severe pneumonia were selected and randomly divided into two groups, with 30 cases in each group. Control group was treated with antibiotics according to the experience, and observation group was treated with antibiotics under the guidance of CPIS. The drug regimen in both groups was tigecycline combined with cefoperazone sodium and sulbactam sodium. The symptom disappearance rate, application time of antibiotics, levels of inflammatory indexes［C reactive protein(CRP), procalcitonin(PCT), white blood cell count(WBC)］ and adverse reactions were compared between the two groups. Results After 2 weeks of treatment, the fever symptoms disappeared in both groups, and there were no significant differences in the disappearance rate of pulmonary rales and expectoration between the two groups(P>0.05). The application time of antibiotics in the observation group was(7.38±2.66)days, which was significantly shorter than(9.82±2.89)days in the control group(t=3.403, P=0.001). The levels of CRP, PCT and WBC in both groups after treatment were significantly lower than those before treatment(P<0.05). The incidence of adverse reactions in the observation group was significantly lower than that in the control group(P<0.05). Conclusion Under the guidance of CPIS, tigecycline combined with cefoperazone sodium and sulbactam sodium is safe and effective in the treatment of severe - pneumonia patients, which can shorten the medication time and relieve the symptoms of patients.
-
-
周欣, 姚高琼, 张成志, 等. 重庆市抗菌药物使用调查及干预前后对比分析研究[J]. 重庆医学, 2017, 46(11): 1508-1510. 黄丽君, 郑丽贞. 抗菌药物联合用药现状调查与研究[J]. 中国生化药物杂志, 2017, 37(7): 403-405. 刘华锋, 燕丽, 王磊, 等. 替加环素结合头孢哌酮钠舒巴坦钠治疗多药耐药鲍氏不动杆菌肺部感染患者的临床疗效[J]. 中华医院感染学杂志, 2017, 27(15): 3401-3403 , 3410.
LI T, SHENG M Y, GU T Z, et al. In vitro assessment of cefoperazone-sulbactam based combination therapy for multidrug-resistant Acinetobacter baumannii isolates in China[J]. Journal of Thoracic Disease, 2018, 10(3): 1370-1376.
CHEN C Q, YAN M L, HU C B, et al. Diagnostic efficacy of serum procalcitonin, C-reactive protein concentration and clinical pulmonary infection score in Ventilator-Associated Pneumonia[J]. Medecine Sciences: M/S, 2018, 34(Focus issue F1): 26-32.
石宏哲, 秦铮, 池卫华, 等. 重症肺炎MSCT图像征象、临床肺部感染评分与病情严重程度的相关性研究[J]. 中国CT和MRI杂志, 2019, 17(7): 79-81. 中国医师协会急诊医师分会. 中国急诊重症肺炎临床实践专家共识[J]. 中国急救医学, 2016, 36(2): 97-107. WONGSURAKIAT P, TULATAMAKIT S. Clinical pulmonary infection score and a spot serum procalcitonin level to guide discontinuation of antibiotics in ventilator-associated pneumonia: a study in a single institution with high prevalence of nonfermentative gram-negative bacilli infection[J]. Ther Adv Respir Dis, 2018, 12: 1753466618760134.
PFALLER M A, FLAMM R K, DUNCAN L R, et al. Antimicrobial activity of tigecycline and cefoperazone/sulbactam tested against 18, 386 Gram-negative organisms from Europe and the Asia-Pacific region(2013-2014)[J]. Diagnostic Microbiology and Infectious Disease, 2017, 88(2): 177-183.
CHEN H, LIU Q, CHEN Z, et al. Efficacy of sulbactam for the treatment of Acinetobacter baumannii complex infection: a systematic review and meta-analysis[J]. J Infect Chemother, 2017, 23(5): 278-285.
秦又发, 吴雷, 朱永坤, 等. 替加环素联合头孢哌酮-舒巴坦治疗广泛耐药鲍曼不动杆菌医院获得性肺炎临床疗效观察[J]. 中国感染与化疗杂志, 2015, 15(5): 430-433. GIAMMANCO A, CALÀ C, FASCIANA T, et al. Global assessment of the activity of tigecycline against multidrug-resistant gram-negative pathogens between 2004 and 2014 as part of the tigecycline evaluation and surveillance trial[J]. mSphere, 2017, 2(1): e00310-e00316.
CHEN Z, SHI X. Adverse events of high-dose tigecycline in the treatment of ventilator-associated pneumonia due to multidrug-resistant pathogens[J]. Medicine(Baltimore), 2018, 97(38): e12467.
聂晓莉, 闫春良, 赵秋红, 等. 医院内获得性肺炎抗菌药物的疗效和安全性比较[J]. 中国医院药学杂志, 2015, 35(13): 1225-1227. HARADA K, SEKIYA N, KONISHI T, et al. Predictive implications of albumin and C-reactive protein for progression to pneumonia and poor prognosis in Stenotrophomonas maltophilia bacteremia following allogeneic hematopoietic stem cell transplantation[J]. BMC Infectious Diseases, 2017, 17(1): 638-647.
GARDNER J G, BHAMIDIPATI D R, RUEDA A M, et al. White blood cell counts, alcoholism, and cirrhosis in pneumococcal pneumonia[J]. Open Forum Infectious Diseases, 2017, 4(2): ofx034.
ITO A, ISHIDA T, TOKUMASU H, et al. Impact of procalcitonin-guided therapy for hospitalized community-acquired pneumonia on reducing antibiotic consumption and costs in Japan[J]. Journal of Infection and Chemotherapy: Official Journal of the Japan Society of Chemotherapy, 2017, 23(3): 142-147.
PANDURANGAN A P, ASCHER D B, THOMAS S E, et al. Genomes, structural biology and drug discovery: combating the impacts of mutations in genetic disease and antibiotic resistance[J]. Biochemical Society Transactions, 2017, 45(2): 303-311.
马莹, 李旺, 陈瑶, 等. 某院鲍氏不动杆菌耐药性与抗菌药物使用强度相关性分析[J]. 中华医院感染学杂志, 2020, 30(5): 648-652. 陈求凝, 张雪梅, 谢邦贵, 等. 不同抗菌药物对肺部感染新生儿肠道菌群及消化系统影响的研究[J]. 中华医院感染学杂志, 2018, 28(16): 2531-2534.
计量
- 文章访问数: 410
- HTML全文浏览量: 100
- PDF下载量: 15
下载:
苏公网安备 32100302010246号